NasdaqGS:MDGLBiotechs
Madrigal Pharmaceuticals (MDGL) Stock Valuation As Rezdiffra Data Plans And Mixed Analyst Updates Shape Expectations
Conference spotlight and mixed analyst views put Madrigal Pharmaceuticals (MDGL) in focus
Madrigal Pharmaceuticals (MDGL) is back on investors’ radar after recent analyst commentary on its MASH treatment Rezdiffra and plans to showcase fresh clinical and real world data at the upcoming EASL Congress 2026.
The stock is also drawing attention ahead of Madrigal’s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, where management is expected to discuss...